Acute myeloid leukaemia vaccine - AVAX TechnologiesAlternative Names: Acute myelogenous leukaemia vaccine - AVAX Technologies; L-Vax; Leukaemia vaccine - AVAX Technologies
Latest Information Update: 17 Mar 2008
At a glance
- Originator AVAX Technologies
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 18 May 2000 Phase-II clinical trials for Acute myeloid leukaemia in USA (Intradermal)